Immunogenicity of TNF-Inhibitors

Tumor necrosis factor inhibitors (TNFi) have significantly improved treatment outcome of rheumatic diseases since their incorporation into treatment protocols two decades ago. Nevertheless, a substantial fraction of patients experiences either primary or secondary failure to TNFi due to ineffectiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Atiqi, Sadaf, Hooijberg, Femke, Loeff, Floris C., Rispens, Theo, Wolbink, Gerrit J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055461/
https://www.ncbi.nlm.nih.gov/pubmed/32174918
http://dx.doi.org/10.3389/fimmu.2020.00312

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7055461/
https://www.ncbi.nlm.nih.gov/pubmed/32174918
http://dx.doi.org/10.3389/fimmu.2020.00312

Ejemplares similares